---
title: "MONALEESA-3"
slug: "monaleesa"
date: "2023-12-06"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[Hormone-receptor positive (HER2 negative)-of-metastatic breast cancer]]

# MONALEESA-3

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

åœ¨ä¸€é …åç‚ºMONALEESA-3çš„Phase 3ç ”ç©¶çš„ç¬¬äºŒæ¬¡ä¸­æœŸåˆ†æä¸­ç™¼ç¾ï¼šé‡å°ERé™½æ€§ã€HER2é™°æ€§çš„é€²éšä¹³è…ºç™Œæ‚£è€…ï¼Œä½¿ç”¨ribociclibåŠ fulvestrantç›¸è¼ƒæ–¼åƒ…ä½¿ç”¨fulvestrantï¼Œåœ¨ç¸½é«”ç”Ÿå­˜æœŸä¸Šæœ‰é¡¯è‘—çš„ç›Šè™•

- åœ¨æ–¼42å€‹æœˆæ™‚çš„é ä¼°ç¸½é«”ç”Ÿå­˜ç‡ï¼Œribociclibçµ„ç‚º57.8ï¼… (95ï¼…ä¿¡è³´å€é–“[CI]ç‚º52.0ï¼…è‡³63.2ï¼…) ï¼Œè€Œå®‰æ…°åŠ‘çµ„ç‚º45.9ï¼… (95ï¼… CIç‚º36.9ï¼…è‡³54.5ï¼…) ï¼Œç›¸å°é¢¨éšªçš„æ­»äº¡ç‡ä¸‹é™ â†“ äº†28ï¼… (é¢¨éšªæ¯”ç‚º0.72ï¼›95ï¼… CIç‚º0.57è‡³0.92ï¼›P = 0.00455)
- æ­¤å¤–ï¼Œåœ¨æ¥å—ç¬¬ä¸€ç·šæ²»ç™‚çš„æ‚£è€…ä¸­ï¼Œä½¿ç”¨ribociclibåŠ fulvestrantçš„ä¸­ä½ âœ– ç„¡ç–¾ç—…é€²å±•ç”Ÿå­˜æœŸç‚º33.6å€‹æœˆ (95ï¼… CIç‚º27.1è‡³41.3) ï¼Œè€Œåœ¨å®‰æ…°åŠ‘çµ„ä¸­ç‚º19.2å€‹æœˆ (95ï¼… CIç‚º14.9è‡³23.6) ã€‚

## Ribociclib plus Fulvestrant for Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

- **Design:** Phase 3, randomized clinical trial
- **Number of patients:** Not reported
- **Patients characteristics:** Postmenopausal patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, receiving first-line or second-line treatment
- **Agent:** Ribociclib plus Fulvestrant vs. Placebo plus Fulvestrant
- **Treatment line:** First-line or second-line treatment
- **Trial Name/NCT Number:** MONALEESA-3 ClinicalTrials.gov number, NCT02422615

### Comparison of Ribociclib plus Fulvestrant vs. Placebo plus Fulvestrant

| Endpoints                  | Ribociclib plus Fulvestrant               | Placebo plus Fulvestrant                  |
| -------------------------- | ----------------------------------------- | ----------------------------------------- |
| PFS (first-line treatment) | Median 33.6 months (95% CI, 27.1 to 41.3) | Median 19.2 months (95% CI, 14.9 to 23.6) |
| Overall survival           | 42 months was 57.8%                       | 45.9%                                     |
| Response rate              | Not reported                              | Not reported                              |

- **Other findings:**
  - No new safety signals were observed.

### Summary

Ribociclib plus Fulvestrant significantly improved overall survival compared to Placebo plus Fulvestrant in postmenopausal patients with hormone-receptor-positive, HER2-negative advanced breast cancer receiving first-line or second-line treatment. The benefit was consistent across most subgroups. Median progression-free survival was also improved in patients receiving first-line treatment. No new safety signals were observed.
